• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Gritstone bio Inc.

    10/7/24 5:01:07 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GRTS alert in real time by email
    SC 13G 1 tm2425691d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. __)

     

    Gritstone bio, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    39868T105

    (CUSIP Number)

     

    September 30, 2024 

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 39868T105

    1

    Name of Reporting Person

     

    RedCo II Master Fund, L.P.

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (A) ¨

     

    (B) ¨

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    Cayman Islands

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with
     

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    8,197,331 (consisting of 0 shares of Common Stock and 8,197,331 Warrant Shares under the Beneficial Ownership Blocker) (1)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    8,197,331 (consisting of 0 shares of Common Stock and 8,197,331 Warrant Shares under the Beneficial Ownership Blocker) (1)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    8,197,331 (consisting of 0 shares of Common Stock and 8,197,331 Warrant Shares under the Beneficial Ownership Blocker) (1)

    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11

    Percent of Class Represented by Amount in Row (9)

     

    6.2% (0% derived from beneficial ownership of Common Stock and 6.2% derived from beneficial ownership of Warrant Shares under the Beneficial Ownership Blocker) (2)

    12

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1) The beneficial ownership of RedCo II Master Fund, L.P. (“RedCo II”) is comprised solely of 8,197,331 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants to Purchase Common Stock (the “Warrants” and the shares issuable thereunder, the “Warrant Shares”) under the Beneficial Ownership Blocker (as defined below). The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of RedCo II, and also may be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Pursuant to the terms of the Warrants, a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, and any such exercise shall be void ab initio, to the extent (but only to the extent) that after giving effect to such issuance after exercise, the holder (together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates), would beneficially own in excess of 9.99% (the “Beneficial Ownership Limitation”) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares issued upon exercise of the Warrant (the “Beneficial Ownership Blocker”). The Beneficial Ownership Limitation may be changed at a holder’s election upon 61 days’ notice to the Issuer. The 8,197,331 Warrant Shares reported as beneficially owned by RedCo II in this Schedule 13G represent the maximum amount of Common Stock issuable to RedCo II under the Beneficial Ownership Blocker (calculated in accordance with footnote (2) below).

     

    (2) Percentage based on 131,306,404 shares of Common Stock deemed outstanding, based on the outstanding shares of Common Stock reported by the Issuer in its quarterly report on Form 10-Q for the quarterly period ended June 30, 2024 filed with the SEC on August 13, 2024 (the “Form 10-Q”), the Warrant Shares issued upon exercise of certain Warrants since the filing of the Form 10-Q, and the reported Warrant Shares, which, due to the Beneficial Ownership Limitation, is the maximum number of shares that could be issued to RedCo II upon exercise of the Warrants.

     

     

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Gritstone bio, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    5959 Horton Street, Suite 300

    Emeryville, California 94608

     

    Item 2.

     

    (a)Name of Each Person Filing (each, a “Reporting Person”)

     

    RedCo II Master Fund, L.P.

     

    (b)Address of Principal Business office or, if None, Residence

     

    c/o Redmile Group, LLC

    One Letterman Drive

    Building D, Suite D3-300

    The Presidio of San Francisco

    San Francisco, California 94129

     

    (c)Citizenship

     

    Cayman Islands

     

    (d)Title of Class of Securities

     

    Common Stock, $0.0001 par value per share

     

    (e)CUSIP Number

     

    39868T105

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e)¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _______

     

     

     

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    8,197,331 (consisting of 0 shares of Common Stock and 8,197,331 Warrant Shares under the Beneficial Ownership Blocker)*
     

    (b)Percent of class:

     

    6.2% (0% derived from beneficial ownership of Common Stock and 6.2% derived from beneficial ownership of Warrant Shares under the Beneficial Ownership Blocker)**

     

    (c)Number of shares as to which RedCo II Master Fund, L.P. has:

     

    (i)Sole power to vote or to direct the vote: 0
    (ii)Shared power to vote or to direct the vote: 8,197,331 (consisting of 0 shares of Common Stock and 8,197,331 Warrant Shares under the Beneficial Ownership Blocker)*
    (iii)Sole power to dispose or to direct the disposition of: 0
    (iv)Shared power to dispose or to direct the disposition of: 8,197,331 (consisting of 0 shares of Common Stock and 8,197,331 Warrant Shares under the Beneficial Ownership Blocker)*

     

    *RedCo II’s beneficial ownership of the Issuer’s Common Stock is comprised solely of 8,197,331 Warrant Shares issuable under the Beneficial Ownership Blocker. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of RedCo II, and also may be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, if the Beneficial Ownership Blocker applies. The 8,197,331 shares of Common Stock reported as beneficially owned by RedCo II in this Schedule 13G represent the maximum amount of Warrant Shares issuable under the Beneficial Ownership Blocker.

     

    **Percentage based on 131,306,404 shares of Common Stock deemed outstanding, based on the outstanding shares of Common Stock reported by the Issuer in Form 10-Q, the Warrant Shares issued upon exercise of certain Warrants since the filing of the Form 10-Q, and the reported Warrant Shares, which, due to the Beneficial Ownership Limitation, is the maximum number of shares that could be issued to RedCo II upon exercise of the Warrants.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    N/A.

     

    Item 8.Identification and Classification of Members of the Group.

     

    N/A.

     

     

     

     

    Item 9.Notice of Dissolution of Group.

     

    N/A.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 7, 2024

     

      RedCo II Master Fund, L.P.
      By: Redco II (GP), LLC, its general partner
       
      /s/ Jeremy C. Green
      Name: Jeremy C. Green
      Title: Managing Member

     

     

     

    Get the next $GRTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRTS

    DatePrice TargetRatingAnalyst
    10/1/2024Mkt Outperform → Mkt Perform
    JMP Securities
    2/28/2024$4.00Mkt Outperform
    JMP Securities
    3/31/2023Outperform
    Evercore ISI
    3/28/2023$8.00Buy
    B. Riley Securities
    10/31/2022$6.00Overweight
    Piper Sandler
    8/22/2022$2.00Neutral → Sell
    Goldman
    12/15/2021$15.00Neutral
    Goldman
    10/15/2021$20.00Buy
    BTIG Research
    More analyst ratings

    $GRTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Gritstone bio Inc.

      SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)

      11/6/24 5:34:44 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Gritstone bio Inc.

      SC 13G - Gritstone bio, Inc. (0001656634) (Subject)

      10/7/24 5:01:07 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Gritstone bio Inc.

      SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)

      7/8/24 4:32:39 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure

      Voluntarily Files for Chapter 11 Restructuring Strategic Alternatives Process Continues with Interest from Parties Gritstone bio, Inc. (NASDAQ:GRTS) ("Gritstone" or the "Company"), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Gritstone intends to use the court-administered restructuring process to preserve value and support its ongoing strategic alternatives process. The Company is in discussions with a party to act as a stalking horse bidder or plan sponsor and intends to

      10/10/24 5:50:00 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

      --Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.79 [95% CI, 0.42-1.50])-- -- 38% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.62 [95% CI, 0.23-1.70]) -- -- Strength of neoantigen specific T cell responses in GRANITE patients appears to associate with progression-free survival -- GRANITE was generally well-tolerated with no treatment discontinuations due to adverse events– -- Overa

      9/30/24 4:05:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

      -- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer -- -- Presentations at AACR 2024 and ESCMID Global 2024 demonstrate the broad potential of Gritstone's oncology and infectious disease vaccines -- -- Cash, cash equivalents, marketable securities and restricted cash of $61.7 million as of June 30, 2024 -- EMERYVILLE, C

      8/13/24 4:05:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    Financials

    Live finance-specific insights

    See more
    • Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024

      -- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. To access by phone, dial: 1-877-407-4018Conference ID: 13746126To access by webcast, visit: https://viavid.webcasts.com/starthere.jsp?ei=1667088&tp_key=d0e680f7aa While not required, it is recommended yo

      5/2/24 4:05:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates

      -- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE (personalized vaccine in first-line metastatic microsatellite-stable colorectal cancer [MSS-CRC]) to date; 71 of 80 patients (initial target) enrolled as of May 10, 2023 -- -- Gritstone prioritizing GRANITE; expanding Phase 2 from 80 to 100 patients, enrollment completion expected in 3Q2023, preliminary data on approximately 50 patients expected in 1Q2024 -- -- Cash, cash equivalents, marketable securities, and restricted cash of $153.2 million as of March 31, 2023 -- -- Gritstone to host conference call today at 4:30pm ET -- EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ

      5/11/23 4:05:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 11, 2023

      EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report its first quarter 2023 financial results and provide a corporate update following market close on Thursday, May 11, 2023. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. Live Conference Call & WebcastToll Free: 1-888-999-6281International: 1-848-280-6550Conference ID: 1754341Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1612896&tp_key=c6c637ac24 While not required, it is recommended you join five minutes prior to the

      5/3/23 7:00:00 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Allen Andrew R gifted 650,000 shares, decreasing direct ownership by 25% to 985,360 units (SEC Form 4)

      4 - Gritstone bio, Inc. (0001656634) (Issuer)

      6/26/24 9:25:58 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Fisher Clare

      4 - Gritstone bio, Inc. (0001656634) (Issuer)

      6/20/24 6:23:33 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Agarwal Shefali

      4 - Gritstone bio, Inc. (0001656634) (Issuer)

      6/20/24 6:19:11 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors

      EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Mr. Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The company also announced that Steve Krognes will not stand for re-election at the 2024 Annual Meeting. "We are excited to welcome Stephen Webster to our Board of Directors at this important and excit

      4/29/24 7:00:00 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

      -- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models -- -- Combined with Gritstone's vaccine vectors, EDGE has demonstrated best-in-class potential in identifying neoantigens capable of eliciting T cell immune responses for robust and durable immunity -- EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today presented an upd

      4/8/24 7:00:00 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors

      EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company's strategic initiatives and commercialization efforts. Dr. Hawryluk currently serves as Executive Vice President and Chief Business Officer of Gritstone bio, Inc (NASDAQ:GRTS). Recognized by Pharmaceutical Executive magazine as a leading business executive in the pharma and biotech industries, Dr. Hawryluk has played key roles in bridging the gap between scientific discovery and the commercial application of scientific breakthroughs. As a named invento

      12/5/22 8:30:00 AM ET
      $GRTS
      $POAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Specialties

    $GRTS
    SEC Filings

    See more
    • Gritstone bio Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

      8-K - Gritstone bio, Inc. (0001656634) (Filer)

      10/16/24 4:06:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Regulation FD Disclosure

      8-K - Gritstone bio, Inc. (0001656634) (Filer)

      10/10/24 8:29:59 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Gritstone bio Inc.

      8-K - Gritstone bio, Inc. (0001656634) (Filer)

      9/30/24 8:05:58 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Gritstone bio downgraded by JMP Securities

      JMP Securities downgraded Gritstone bio from Mkt Outperform to Mkt Perform

      10/1/24 7:33:47 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Gritstone bio with a new price target

      JMP Securities initiated coverage of Gritstone bio with a rating of Mkt Outperform and set a new price target of $4.00

      2/28/24 6:17:40 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Gritstone bio

      Evercore ISI initiated coverage of Gritstone bio with a rating of Outperform

      3/31/23 8:59:35 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care